Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Comparative effectiveness research for antipsychotic medications: how much is enough?

Meltzer DO, Basu A, Meltzer HY.

Health Aff (Millwood). 2009 Sep-Oct;28(5):w794-808. doi: 10.1377/hlthaff.28.5.w794. Epub 2009 Jul 21.

3.

What do large scale studies of medication in schizophrenia add to our management strategies?

Agius M, Davis A, Gilhooley M, Chapman S, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):323-8. Review.

4.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
5.

Cost-effectiveness of atypical antipsychotic medications versus conventional medication.

Hanrahan P, Luchins DJ, Fabian R, Tolley G.

Expert Opin Pharmacother. 2006 Sep;7(13):1749-58. Review.

PMID:
16925502
6.

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association.

Schizophr Res. 2008 Mar;100(1-3):20-38. doi: 10.1016/j.schres.2007.11.033. Epub 2008 Feb 19. Review.

PMID:
18243663
7.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
8.

Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.

Hamann J, Leucht S, Kissling W.

Pharmacopsychiatry. 2003 Jan;36(1):18-26. Review.

PMID:
12649770
9.

Antipsychotics and metabolics in the post-CATIE era.

Meyer JM.

Curr Top Behav Neurosci. 2010;4:23-42. Review.

PMID:
21312396
10.

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

Leucht S, Kissling W, Davis JM.

Psychol Med. 2009 Oct;39(10):1591-602. doi: 10.1017/S0033291709005455. Epub 2009 Apr 1. Review.

PMID:
19335931
11.
12.

Pharmacoeconomics of antipsychotic drug therapy.

Hargreaves WA, Shumway M.

J Clin Psychiatry. 1996;57 Suppl 9:66-76. Review.

PMID:
8823354
13.
14.
15.

Medicaid policies to contain psychiatric drug costs.

Koyanagi C, Forquer S, Alfano E.

Health Aff (Millwood). 2005 Mar-Apr;24(2):536-44. Review.

PMID:
15757941
16.

Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.

Obradovic M, Mrhar A, Kos M.

Int J Clin Pract. 2007 Dec;61(12):1979-88. Review.

PMID:
17997804
17.

Antipsychotic safety and efficacy concerns.

Meyer JM.

J Clin Psychiatry. 2007;68 Suppl 14:20-6. Review.

18.

Formulary decisions and health economics.

Glazer WM.

J Clin Psychiatry. 1998;59 Suppl 19:23-9. Review.

19.

Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.

Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS.

Ann Intern Med. 2012 Oct 2;157(7):498-511. Review.

PMID:
22893011

Supplemental Content

Support Center